Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 19, 2025 16:20 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and...